| Literature DB >> 24384074 |
Pearl Bakhru1, Natalie Sirisaengtaksin1, Emily Soudani1, Seema Mukherjee1, Arshad Khan1, Chinnaswamy Jagannath2.
Abstract
Tuberculosis is a major cause of death in mankind and BCG vaccine protects against childhood but not adult tuberculosis. BCG avoids lysosomal fusion in macrophages decreasing peptides required for activating CD4 T cells and Th1 immunity while suppressing the expression of MHC-II by antigen presenting cells (APCs). An in vitro model of antigen presentation showed that ligands for TLR-9, 7, 4 and 1/2 increased the ability of APCs to present antigen-85B of BCG to CD4 T cells, which correlated with an increase in MHC-II expression. TLR-activation led to a down-regulation of MARCH1 ubiquitin ligase which prevents the degradation of MHC-II and decreased IL-10 also contributed to an increase in MHC-II. TLR-activation induced up-regulation of MHC-II was inhibited by the blockade of IRAK, NF-kB, and MAPKs. TLR-7 and TLR-9 ligands had the most effective adjuvant like effect on MHC-II of APCs which allowed BCG vaccine mediated activation of CD4 T cells. Published by Elsevier Inc.Entities:
Keywords: Antigen processing; BCG vaccine; CD80; CD86; Dendritic cells; IL-10; MARCH1 ubiquitin ligase; MHC-II; Macrophage; Toll-like receptor (TLR)
Mesh:
Substances:
Year: 2013 PMID: 24384074 PMCID: PMC4096037 DOI: 10.1016/j.cellimm.2013.11.007
Source DB: PubMed Journal: Cell Immunol ISSN: 0008-8749 Impact factor: 4.868